Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mesoblast gets $A13.44mm via private financing

Executive Summary

Mesoblast (stem cell therapies for orthopedic conditions) raised $A13.44mm ($11.8mm) through the private placement of 10.5mm shares priced at $A1.28 each (a 5% discount) to Australian institutional and sophisticated investors. The company will use the funds to begin Phase II trials of allogeneic adult stem cells for use in the repair and regeneration of bone and cartilage.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Venture Financing

Related Companies